This trial will test a new PET imaging method to help diagnose coronary artery disease (CAD) in 182 participants at 10 sites in the US & Europe. The participants will receive two doses of a special imaging agent and have safety follow-ups.
- Coronary Artery Disease
1 Primary · 4 Secondary · Reporting Duration: 30 days
2 Treatment Groups
[O-15]-Water PET Myocardial Perfusion Imaging (MPI)
1 of 2
[O-15]-Water PET Cardiac Perfusion Imaging
1 of 2
215 Total Participants · 2 Treatment Groups
Primary Treatment: [O-15]-Water PET Myocardial Perfusion Imaging (MPI) · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many volunteers are being recruited for this research?
"Affirmative. The clinical trial's page on clinicaltrials.gov reveals that it is presently looking for participants, after first being posted in May 8th 2022 and last edited on March 14th 2023. This study needs to enroll 215 individuals across 3 different medical sites." - Anonymous Online Contributor
Are there any vacancies left in this clinical research project?
"Affirmative. According to clinicaltrials.gov, this medical study is presently enrolling participants and was initially posted on May 8th 2022. It has been updated as recently as March 14th 2023 and requires 215 patients across 3 sites for completion." - Anonymous Online Contributor
Has the [O-15]-Water PET Myocardial Perfusion Imaging (MPI) been given clearance by the FDA?
"Our Power team gave [O-15]-Water PET Myocardial Perfusion Imaging (MPI) a safety rating of 3, as the existing evidence from Phase 3 clinical trials indicate it is both efficacious and safe." - Anonymous Online Contributor